

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
File Information Unit, Room 2E04
2900 Crystal Drive
Arlington, VA 22202-3514

Telephone: (703) 308-2733

In re Application of

Application Number

07/943852

Filed

9/11/92

Paper No. 27

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____.

United States Patent Number 6284471, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____.

Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General

A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site (www.uspto.gov). Terminals that allow access to Public PAIR are available in the Public Search Room. The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the **Office of Public Records** upon payment of the appropriate fee (37 CFR 1.19(b)).

For published applications that are still pending, a member of the public may obtain a **copy** of: the file contents; the pending application as originally filed; or any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a **copy** of: the file contents; the pending application as originally filed; or any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a **copy** of the pending application as originally filed.

Signature

Typed or printed name

Date

FOR PTO USE ONLY

Approved by:

RECEIVED

(initials)

Unit:

MAR 22 2007

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US006284471B1

(12) **United States Patent**
Le et al.

(10) **Patent No.:** **US 6,284,471 B1**
(45) Date of Patent: **Sep. 4, 2001**

(54) **ANTI-TNFA ANTIBODIES AND ASSAYS EMPLOYING ANTI-TNFA ANTIBODIES**

(75) Inventors: Junming Le, Jackson Heights; Jan Vilcek, New York, both of NY (US); Peter Dadonna, Palo Alto, CA (US); John Ghrayeb, Thorndale; David Knight, Berwyn, both of PA (US); Scott A. Siegel, Westborough, MA (US)

(73) Assignees: New York University Medical Center, New York, NY (US); Centocor, Inc., Malvern, PA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 08/192,093

(22) Filed: Feb. 4, 1994

Related U.S. Application Data

(63) Continuation-in-part of application No. 08/010,406, filed on Jan. 29, 1993, now abandoned, and a continuation-in-part of application No. 08/013,413, filed on Feb. 2, 1993, now abandoned, which is a continuation-in-part of application No. 07/943,852, filed on Sep. 11, 1992, now abandoned, which is a continuation-in-part of application No. 07/853,606, filed on Mar. 18, 1992, now abandoned, which is a continuation-in-part of application No. 07/670,827, filed on Mar. 18, 1991, now abandoned.

(51) Int. Cl. **7** C07K 16/24; A61K 39/395; C12N 15/00; G01N 33/53

(52) U.S. Cl. 435/7.1; 435/69.6; 435/70.21; 530/387.3; 530/388.23; 530/391.3; 424/133.1; 424/139.1; 424/141.1

(58) Field of Search 530/387.3, 388.23, 530/391.3; 435/7.1, 240.27, 172.2, 70.21

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,603,106 7/1986 Cerami et al.
 4,822,776 4/1989 Cerami et al.
 5,237,024 * 8/1993 Molley et al.

FOREIGN PATENT DOCUMENTS

0212489A2 3/1987 (EP).
 0218868A2 4/1987 (EP).
 0260610A2 3/1988 (EP).
 0288088A2 10/1988 (EP).
 0308378A2 3/1989 (EP).
 0350690A2 * 1/1990 (EP).
 0351789A2 * 1/1990 (EP).
 0380068A1 8/1990 (EP).
 0393438A3 10/1990 (EP).
 0398327A1 11/1990 (EP).
 0412486A1 2/1991 (EP).
 0433900A1 6/1991 (EP).
 0526905A2 2/1993 (EP).
 9102078 * 2/1991 (WO).
 WO91/02078 2/1991 (WO).
 91/09967 * 7/1991 (WO).
 WO92/07076 4/1992 (WO).
 WO92/13095 8/1992 (WO).

WO92/11383 9/1992 (WO).

OTHER PUBLICATIONS

N. Sites, DP. et al (ed.) *Medical Immunology*, Appleton & Lange, p. 101, 1997.*
 Moller et al., *Cytokine* 2: 162-9, 1990.*
 Morrison, Suenie 229: 1201-7, 1985.*
 Paulus, Behring Inst. Mitt. 78: 118-321 1985.*
 CA AN CA 118(S):37840n, Le et al., WO9216553A1, Oct. 1992., 105pp.*
 Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," *Nature*, 316:552-554 (1985).
 Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," *Science*, 229:869-871 (1985).
 Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," *Science*, 229:1202-1207 (1985).
 Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," *Biochem. & Biophys. Res. Comm.*, 137 (2) :847-854 (1986).
 Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," *J. of Immun. Methods*, 96:57-62 (1987).
 Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," *J. Exp. Med.*, 166:1280-1289 (1987).
 Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," *Hybridoma*, 6 (3) :305-311 (1987).
 Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," *Hybridoma*, 6 (4) :359-370 (1987).
 Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," *Hybridoma*, 6 (5) :489-507 (1987).
 Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," *Nature*, 330:662-664 (1987).

(List continued on next page.)

Primary Examiner—Anthony C. Caputa

Assistant Examiner—Karen A. Canella

(74) Attorney, Agent, or Firm—Hamilton, Brook, Smith & Reynolds, P.C.

(57)

ABSTRACT

Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.